Raising Capital in Life Sciences in 2022-2023: What Works?
By

Raising money in the capital markets for a biopharma or life sciences company over the last few years has been quite a roller coaster ride. Funding among U.S. biotech startups reached a record high of $77 billion in 2021 (Crunchbase), as investors were attracted to expanding opportunities in genetics, therapeutics…Read More

Read More
Memo to the C-Suite: Do the Opposite of What your Gut is Telling You
By

This too shall pass……But don’t stick your head in the sand while you are waiting Thoughts for Corporate Officers (CEO, CFO) of publicly-traded companies from the perspective of an experienced Public Company Corporate Officer, Sell-Sider (Analyst, Banker, Institutional Salesman) and Buy-Sider (Hedge Fund Manager) Ancient Chinese Curse “May you live…Read More

Read More